Analyst Price Targets — LLY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 2:09 pm | — | UBS | $1,376.00 | $1,177.33 | TheFly | Eli Lilly price target raised to $1,376 from $1,370 at Truist |
| August 6, 2026 12:08 pm | — | Cantor Fitzgerald | $1,410.00 | $1,181.00 | TheFly | Eli Lilly price target raised to $1,410 from $1,350 at Cantor Fitzgerald |
| August 6, 2026 11:36 am | — | Morgan Stanley | $1,419.00 | $1,169.86 | TheFly | Eli Lilly price target raised to $1,419 from $1,347 at Morgan Stanley |
| August 6, 2026 10:09 am | Mohit Bansal | Wells Fargo | $1,330.00 | $1,169.86 | StreetInsider | Eli Lilly (LLY) PT Raised to $1,330 at Wells Fargo |
| August 6, 2026 9:07 am | Evan Seigerman | BMO Capital | $1,400.00 | $1,169.86 | StreetInsider | Eli Lilly (LLY) PT Raised to $1,400 at BMO Capital |
| July 14, 2026 10:20 am | — | Bernstein | $1,385.00 | $1,185.08 | StreetInsider | Eli Lilly (LLY) PT Raised to $1,385 at Bernstein SocGen GroupMember Login |
| July 13, 2026 2:01 pm | — | UBS | $1,425.00 | $1,189.91 | TheFly | Eli Lilly price target raised to $1,425 from $1,250 at UBS |
| July 13, 2026 10:51 am | — | Guggenheim | $1,273.00 | $1,188.58 | StreetInsider | Eli Lilly (LLY) PT Raised to $1,273 at GuggenheimMember Login |
| July 9, 2026 12:29 pm | — | UBS | $1,370.00 | $1,222.13 | TheFly | Eli Lilly price target raised to $1,370 from $1,281 at Truist |
| July 8, 2026 12:52 pm | — | Truist Financial | $1,370.00 | $1,227.07 | StreetInsider | Eli Lilly (LLY) PT Raised to $1,370 at Truist SecuritiesMember Login |
Latest News for LLY
Eli Lilly's tirzepatide is showing potential across autoimmune diseases. The medicine could earn additional indications and attract broader insurance coverage over time.
Aspen Pharmacare expects African sales of Eli Lilly's blockbuster weight-loss and diabetes drug Mounjaro to exceed 2 billion rand ($124 million) in its current financial year, buoyed by surging demand in South Africa and planned launches in Nigeria and Kenya.
Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why the real opportunity may still be ahead.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Prefer to listen? Hear this as a ~5-minute audio briefing on The GuruFocus Brief.Stock NewsBond yields surge to multi-year highs: The 10-year U.S. Treasury yiel
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.